During a Targeted Oncology case-based event, Chung-Han Lee, MD, PhD, and Bradley A. McGregor, MD, discussed the case of a patient with recurrent metastatic renal cell carcinoma and that of a patient at risk of recurrence following resection.
At a live virtual event, Robert J. Motzer, MD, discussed the
risk factors for classifying patients with advanced renal
cell carcinoma (RCC) and data from several phase 3 trials of combination regimens.
During a Targeted Oncology case-based roundtable event, Chandler Park, MD, discussed the preferred first-line treatment options including tyrosine kinase inhibitor/immunotherapy combinations for metastatic clear cell renal cell carcinoma.
Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.
Data regarding the triplet combination of nivolumab, ipilimumab, and cabozantinib show clinical activity across multiple tumor
types, giving a preview of future outcomes in patients with untreated, advanced renal cell carcinoma.
Results from the phase 3 CLEAR trial showed lenvatinib plus everolimus to have a statistically significant improvement in progression-free survival and objective response rate compared with those given sunitinib.